In situ analysis of CCR8 ⁺ regulatory T cells in lung cancer: suppression of GzmB ⁺ CD8 ⁺ T cells and prognostic marker implications.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

T-Lymphocytes, Regulatory*/immunology ; T-Lymphocytes, Regulatory*/metabolism ; Lung Neoplasms*/immunology ; Lung Neoplasms*/pathology ; Lung Neoplasms*/mortality ; Lung Neoplasms*/metabolism ; Lung Neoplasms*/surgery ; CD8-Positive T-Lymphocytes*/immunology ; CD8-Positive T-Lymphocytes*/metabolism ; Receptors, CCR8*/metabolism ; Receptors, CCR8*/immunology ; Granzymes*/metabolism ; Tumor Microenvironment*/immunology; Humans ; Prognosis ; Female ; Male ; Aged ; Middle Aged ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/metabolism ; Lymphocytes, Tumor-Infiltrating/immunology ; Lymphocytes, Tumor-Infiltrating/metabolism ; Biomarkers, Tumor/metabolism ; Aged, 80 and over ; Adult

Background: CCR8-expressing regulatory T cells (Tregs) are selectively localized within tumors and have gained attention as potent suppressors of anti-tumor immunity. This study focused on CCR8 ⁺ Tregs and their interaction with CD8 ⁺ T cells in the tumor microenvironment of human lung cancer. We evaluated their spatial distribution impact on CD8 ⁺ T cell effector function, specifically granzyme B (GzmB) expression, and clinical outcomes.
Methods: A total of 81 patients with lung squamous cell carcinoma (LSCC) who underwent radical surgical resection without preoperative treatment were enrolled. Histological analyses were performed, utilizing an automated image analysis system for double-stained immunohistochemistry assays of CCR8/Foxp3 and GzmB/CD8. We investigated the association of CCR8 ⁺ Tregs and GzmB ⁺ CD8 ⁺ T cells in tumor tissues and further evaluated the prognostic impact of their distribution profiles.
Results: Histological evaluation using the region of interest (ROI) protocol showed that GzmB expression levels in CD8 ⁺ T cells were decreased in areas with high infiltration of CCR8 ⁺ Tregs, suggesting a suppressive effect of CCR8 ⁺ Tregs on T cell cytotoxicity in the local tumor microenvironment. Analysis of the association with clinical outcomes showed that patients with more CCR8 ⁺ Tregs and lower GzmB expression, represented by a low GzmB/CCR8 ratio, had worse progression-free survival.
Conclusions: Our data suggest that local CCR8 ⁺ Treg accumulation is associated with reduced CD8 ⁺ T cell cytotoxic activity and poor prognosis in LSCC patients, highlighting the biological role and clinical significance of CCR8 ⁺ Tregs in the tumor microenvironment. The GzmB/CCR8 ratio may be a useful prognostic factor for future clinical applications in LSCC.
(© 2024. The Author(s).)

Adv Anat Pathol. 2017 Sep;24(5):235-251. (PMID: 28777142)
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. (PMID: 30285222)
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. (PMID: 22419253)
Immunity. 2019 Feb 19;50(2):302-316. (PMID: 30784578)
Br J Cancer. 2017 Aug 8;117(4):451-460. (PMID: 28704840)
J Immunother Cancer. 2021 Feb;9(2):. (PMID: 33589525)
Clin Cancer Res. 2015 Jun 1;21(11):2635-43. (PMID: 25680376)
Ann Surg. 2023 Mar 1;277(3):e528-e537. (PMID: 34334651)
Lancet Oncol. 2021 Feb;22(2):198-211. (PMID: 33476593)
Lancet. 2018 May 26;391(10135):2128-2139. (PMID: 29754777)
J Exp Med. 2021 Jun 7;218(6):. (PMID: 33900375)
Clin Cancer Res. 2019 Mar 1;25(5):1526-1534. (PMID: 30201760)
Annu Rev Immunol. 2020 Apr 26;38:541-566. (PMID: 32017635)
Sci Rep. 2022 Mar 30;12(1):5377. (PMID: 35354899)
Cell Res. 2017 Jan;27(1):109-118. (PMID: 27995907)
Clin Breast Cancer. 2022 Dec;22(8):e901-e915. (PMID: 36089459)
J Immunol. 2023 Aug 15;211(4):673-682. (PMID: 37350632)
Cancer Res. 2021 Jun 1;81(11):2983-2994. (PMID: 33757978)
Br J Cancer. 2023 Jun;128(12):2175-2185. (PMID: 37016103)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Cancer Immunol Res. 2018 Apr;6(4):481-493. (PMID: 29467127)
Nat Immunol. 2003 Apr;4(4):330-6. (PMID: 12612578)
Nat Genet. 2016 Jun;48(6):607-16. (PMID: 27158780)
N Engl J Med. 2020 Oct 1;383(14):1328-1339. (PMID: 32997907)
BMC Cancer. 2020 Aug 5;20(1):731. (PMID: 32758195)
Immunity. 2016 Nov 15;45(5):1122-1134. (PMID: 27851913)
Blood. 2005 Aug 1;106(3):1008-11. (PMID: 15840697)
Cell. 2008 May 30;133(5):775-87. (PMID: 18510923)
Proc Natl Acad Sci U S A. 2022 Feb 15;119(7):. (PMID: 35140181)
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. (PMID: 16344461)
J Natl Cancer Inst. 2015 Feb 03;107(3):. (PMID: 25650315)
Immunity. 2016 Nov 15;45(5):1135-1147. (PMID: 27851914)
J Inflamm (Lond). 2015 Nov 23;12:63. (PMID: 26604855)
Oncoimmunology. 2022 Nov 4;11(1):2141007. (PMID: 36352891)
Nat Cancer. 2022 Oct;3(10):1151-1164. (PMID: 36038778)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Nat Med. 2016 Jun;22(6):679-84. (PMID: 27111280)
Cancer Immunol Immunother. 2010 May;59(5):653-61. (PMID: 19908042)
Ann Oncol. 2021 Oct;32(10):1236-1244. (PMID: 34311075)
J Clin Oncol. 2013 Feb 1;31(4):490-8. (PMID: 23269987)
Br J Cancer. 2014 May 13;110(10):2551-9. (PMID: 24675384)
Ann Oncol. 2016 Feb;27(2):225-32. (PMID: 26578726)

Keywords: CCR8; Cytotoxic T cells; Lung cancer; Regulatory T cells; Tumor immunity

0 (Receptors, CCR8)
EC 3.4.21.- (Granzymes)
0 (CCR8 protein, human)
EC 3.4.21.- (GZMB protein, human)
0 (Biomarkers, Tumor)

Date Created: 20240523 Date Completed: 20240524 Latest Revision: 20240603

20240603

PMC11112935

10.1186/s12885-024-12363-x

38783281